Psoriatic arthritis

FDA%20approved.jpg (keep)

TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis

Jack Cush, MD

On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active psoriatic arthritis (PsA) based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. Deucravacitinib, an oral selective tyrosine kinase 2 (TYK2)
Read Article
FDA has approved deucravacitinib (Sotyktu) the Treatment of Adults with Active Psoriatic Arthritis based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials. Sotyktu is the only tyrosine kinase 2 (TYK2) inhibitor to be approved for PsA https://t.co/8xBrgPfENH
Dr. John Cush @RheumNow( View Tweet )
DERM on RheumNow PODCAST (February 2026) The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, and other CTD skin disorders. dermatology drugs, biologics, JAKs - their use, efficacy, https://t.co/4ub0MeY9vF
Dr. John Cush @RheumNow( View Tweet )
Retrospective study of 1553 IBD pts taking biologics or JAKi, w/ 5+ yrs of F/U, 6.8% developed MSK Sxs, with one-third subsequently Dx w/ SpA. HLA-B27 positivity (HR 3.7) and higher UC disease activity (HR 1.57) were associated with an increased risk of SpA. https://t.co/I2YSOLhkAb
Dr. John Cush @RheumNow( View Tweet )
What did you miss at RheumNow Live 2026? Our Poster Hall features new data across: • Psoriatic Arthritis • Systemic Lupus Erythematosus • Lupus Nephritis • Vasculitis • Polymyalgia Rheumatica • Axial Spondyloarthritis From Phase III trials to real-world evidence, these https://t.co/nuXGUdmwon
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

SATISFACTION (2.27.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
Danish DERMBIO registry of psoriasis pts Rx w/ biologics. Among 3790 bionaive pts ustekinumab had best 1-5 yr survival vs (ADA & SEC). In 3403 bioexperienced pts, bimekizumab, guselkumab, & risankizumab had highest 2-year drug survival rate. https://t.co/TInyLPMYkb https://t.co/UTPqa9erPU

Links:

Dr. John Cush @RheumNow( View Tweet )
Real-world study of 1202 #PsA pts shows that secukinumab retention rates were lower w/ smoking (79%/73%/72% in never/former/current smokers) but not w/ obesity (72%/77%/77% in normal/overweight/obese), Adh HR signif. higher w/ former (1.32) & current smokers (1.27) https://t.co/1REWmod73W
Dr. John Cush @RheumNow( View Tweet )
Referral Rules to Live By (2.20.2026) Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow. Highlights include referral rules, combination biologics in psoriasis, and don't use JAK inhibitors in pregnancy. https://t.co/thzetw5jwa https://t.co/HTjWyqFqDZ

Links:

Dr. John Cush @RheumNow( View Tweet )
Peripheral manifestations are inconsistently assessed in axSpA trials. b/tsDMARDs have small-to-mod effects on peripheral Sxs & may be underestimated. Assessments in axSpA RCTs were low for periph arthritis 54%, enthesitis in 64% and dactylitis in only 10% of studies. https://t.co/cCNvU1oZMh
Dr. John Cush @RheumNow( View Tweet )
Paradoxical Reactions, Target Selection & the Future of Imaging in Psoriatic Care At RheumNow Live, Dr. Joseph Merola presented a compelling discussion on paradoxical immune reactions in psoriatic disease. He began with a case of a 60-year-old woman with mild psoriasis who, https://t.co/AVIOO42vfP
Dr. John Cush @RheumNow( View Tweet )
J Rheum full read editorial on What HLA-B27 Can—and Cannot—Tell Us!. HLA-B27 also holds prognostic and theragnostic value, given its association with greater structural damage, higher inflammatory burden, and better response to tumor necrosis factor and interleukin 17 inhib. https://t.co/3xNDtePEzn
Dr. John Cush @RheumNow( View Tweet )
Together PSO Trial - Combination Ixekizumab and Tirzepatide Today Lilly announced top line results of the TOGETHER-PsO open-label, Phase 3b trial demonstrating the significant benefits of concomitant ixekizumab (IXE: an IL-17A inhibitor) and tirzepatide (TIR: GLP-1agonist) over https://t.co/YWCjN2NyGM
Dr. John Cush @RheumNow( View Tweet )
Merola RNL26 Shot

Paradoxical Reactions, Target Selection & the Future of Imaging in Psoriatic Care

Audrey Gibson, PA-C

From paradoxical psoriasis to IL-23 vs IL-17 to imaging in PsA, speakers in RheumNow Live's "Decisions in Psoriatic Arthritis" pod delivered valuable, clinically relevant education.

Read Article
Slim,waist,obese,obesity

Together PSO Trial - Combination Ixekizumab and Tirzepatide

Jack Cush, MD

Today Lilly announced top line results of the TOGETHER-PsO open-label, Phase 3b trial demonstrating the significant benefits of concomitant ixekizumab (IXE: an IL-17A inhibitor) and tirzepatide (TIR: GLP-1agonist) over IXE alone.

Read Article
pregnancy,embryo,fetal

Can I Use JAK Inhibitors During Pregnancy?

Jack Cush, MD

In 2020, the ACR Recommendations on Reproductive Health notably avoided firm guidance on the use of JAK inhibitors (JAKi) during pregnancy stating, "There is no available evidence regarding use or safety of the new small- molecule agents, tofacitinib, baricitinib, and apremilast, during

Read Article
RT @ericdeinMD #RNL26 Paradoxical psoriasis with TNF Highest in infliximab Seen highest in IBD, particular Crohn's Palmopustular is most common manifestation May have overlap appearance with psoriaform with eczema, histology with psoriaform spongiotic dermatosis with https://t.co/SKQZgbLQUS
Dr. John Cush @RheumNow( View Tweet )
What did you miss at RheumNow Live 2026? Our Poster Hall features new data across: • Psoriatic Arthritis • Systemic Lupus Erythematosus • Lupus Nephritis • Vasculitis • Polymyalgia Rheumatica • Axial Spondyloarthritis From Phase III trials to real-world evidence, these

Dr. John Cush @RheumNow( View Tweet )

RT @ericdeinMD #RNL26 Arthroplasty risks in RMD AxSpA - Respiratory complications (OR 1.7), PNA (2.2) SLE - complications ass w/ severity/activity. Renal failure, PE, sepsis, stroke, mortality depending on activity PsA - complications related to co-morbidities, not PsA https://t.co/jr0hwh3CPe
Dr. John Cush @RheumNow( View Tweet )
RT @gibson_rheumPAC Arthur Kavanaugh’s RheumNow 2026: Why Do Plain X-Rays in Psoriatic Arthritis? Thought-provoking session on the role of plain radiographs in psoriatic arthritis—not as relics of the past, but as tools that still inform prognosis, function, and long-term

Dr. John Cush @RheumNow( View Tweet )

RT @gibson_RheumPAC Axial PsA remains an area of active investigation. IL-17 inhibitors show consistent benefit, while IL-23 data are emerging—highlighting nuances when axial symptoms drive treatment choice. #RNL26 https://t.co/XFL3Sf8iK4
Dr. John Cush @RheumNow( View Tweet )
RT @Gibson_RheumPAC A good reminder: PsA treatment should be domain-based. Skin, peripheral joints, axial disease, and enthesitis may each favor different pathways. #RNL26 https://t.co/IUCsdlNopo
Dr. John Cush @RheumNow( View Tweet )
RT @ericdeinMD #RNL26 Haque TOGETHER-PsA -P3B study of IXE v IXE + Tirzepatide BMI >27 + 1 wt related co-morbidity -Endpts - ACR and >10% weight reduction -ACR50 improved 33.5% compared to 20% IXE alone (p<0.05) https://t.co/KCpqbg3fHs https://t.co/zktIkdumDk

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Maui Potpourri (2.13.2026)

Jack Cush, MD

Dr. Jack Cush reviews the hot item takeaways from last week's RheumNow.Live 2026.

  1. Diet & Obesity Management in Rheumatology - Uzma Haque, MD
  2. Mitigating risk for Rheum patients undergoing orthopedic surgery - Susan Goodman, MD
  3. Paradoxical skin reactions – Joseph
Read Article
Haque and Goodman

Obesity, Surgery, and Optimizing Patient Care

Eric Dein, MD

Rheumatologic care involves multidisciplinary approaches and collaboration with specialties to treat complex, systemic diseases. While many Pods at RheumNow Live are disease specific, the Pod II focused on Advancing Practice on important and emerging areas affecting rheumatologic patients. This

Read Article

Therapeutic Updates

5-Year Results of an IL-23 Inhibitor in Patients With PsA

AbbVie March 2026
Dr. Alvin Wells and Dr. Shikha Singla share their clinical perspectives on using an IL–23 inhibitor to manage patients with PsA throughout their treatment journey in the context of 5-year data from the KEEPsAKE trial program.
Read Post

Recent Blogs

Advanced Practice Rheum

Methotrexate

Jack Cush, MD
APR MTX Cover
In this session, Dr. Jack Cush reviews methotrexate.
Read Article
Advanced Practice Rheum

Evaluation of Rheumatic Complaints

Jack Cush, MD
Eval of Rheum Complaints Cover Image
Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.
Read Article

Best of 2022: The Enthesitis Challenge in Psoriatic Arthritis

Robert Chao, MD
heel enthesitis spur calcaneal
A colleague of mine once told me an interesting story of how her father, who was a doctor, misdiagnosed his wife with fibromyalgia when she actually had psoriatic arthritis with enthesitis all along. I would venture out and say that the average physician would have trouble evaluating enthesitis because even we, as rheumatologists do! 
Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Podcasts

  • ACR 2025 PsA Topic Podcasts Compilation 6
  • ACR 2025 Daily Podcasts Day4b
  • ACR 2025 Daily Podcasts Day4a
×